



Nomor Dokumen	: FORM7.8V02
---------------	--------------

## Certificate of Analysis

Report Number : 002/TRL-BRI/IV/2026  
COC ID : -  
Quotation ID : -  
Number of Pages : 5 Including Cover  
Customer Sample(s) Identity : -  
Lab Sample ID : BRI-TRL0426-0002  
Priority : Normal / ~~Urgent~~  
Date of Sample(s) Received : 09<sup>th</sup> April 2026  
Date of Analysis Finished : 15<sup>th</sup> April 2026  
Customer : PT. Phyto Labs Indonesia  
Customer Category : Company / ~~Government Institution~~ / ~~School~~ / ~~University~~  
~~Private Individual~~ / ~~Others~~  
Customer Contact Person : (875) 529-3598

Approved by,

**BIOTEK REKAYASA INDONESIA**  
**Firmansyah Karim**  
Director

Wednesday, 15<sup>th</sup> April 2026

### Terms and Conditions

**a)** This report may not be reproduced for any reason except in full and with permission from PT Biotek Rekayasa Indonesia; **b)** In any case PT Biotek Rekayasa Indonesia is not responsible for misuse of the contents of this report; **c)** This report related only to sample(s) received and analyzed if sampling procedure has been done by other party(ies); **d)** If Sample(s) had already taken by other party(ies) or taken not in accordance with the stated method, the report result related to ISO/IEC 17025 accreditation requirements will be affected as described in the quotation previously agreed; **e)** Any complaint will be responded immediately within 48 hours. Complaint received within 2 months after this Report received by the Customer will be followed up as soon as possible. Complaints coming afterwards will not be guaranteed; **f)** Samples will be disposed one month after Customer received this Report (unless requested to be returned upon agreement); **g)** This report contain marks in the form of singular number within bracket and other form of marks that need to be known, as follows:

• (1) is sign for subcontracted test parameter; • (2) is sign for non accredited test parameter or test parameter become unaccredited due to different sample matrix; • (3) is sign for parameter related to sample(s) taken not in accordance with the stated method as described in point d; (4) is sign for in situ test parameter; • NA mean Not Available or Not Applicable




## Certificate of Analysis

### I Sample Description

- 1.1 Subject : E. Kratom 25ppm  
1.2 Batch Number :  
1.3 Expired Date : -  
1.4 Customer Sample(s) Identity : -  
1.5 Lab Sample ID : BRI-TRL0426-0002  
1.6 Matrix : Powder

### II Results

No.	Parameters	Units	Results	Method
1.	Mitragynine	%	85,41	BRI-IK-LAB-006V01 (UHPLC)



This report may not be reproduced for any reason except in full and with permission from  
PT Biotek Rekayasa Indonesia  
Please read full-length Terms and Conditions in the first page




## Certificate of Analysis

### I Sample Description

- 1.1 Subject : E. Kratom 25ppm  
1.2 Batch Number :  
1.3 Expired Date : -  
1.4 Customer Sample(s) Identity : -  
1.5 Lab Sample ID : BRI-TRL0426-0002  
1.6 Matrix : Powder

### II Results



This report may not be reproduced for any reason except in full and with permission from  
PT Biotek Rekayasa Indonesia  
Please read full-length Terms and Conditions in the first page



## Data Interpretation

The  $^1\text{H}$  NMR spectrum of the sample (recorded in MeOD) shows signals consistent with the characteristic proton resonances of mitragynine, confirming the identity of the material. The observed chemical shifts and signal patterns correspond to the expected structural features of mitragynine, including aromatic, olefinic, methoxy, and aliphatic proton regions, which are consistent with previously published spectroscopic data reported by (Hiranita et al., 2019).

Hiranita, T., Leon, F., Felix, J. S., Restrepo, L. F., Reeves, M. E., Pennington, A. E., Obeng, S., Avery, B. A., McCurdy, C. R., McMahon, L. R., & Wilkerson, J. L. (2019). The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats. *Psychopharmacology*, 236(9), 2725–2734.

ORIGINAL

Approved by,



BIOTEK REKAYASA INDONESIA

Firmansyah Karim  
Director

Wednesday, 15<sup>th</sup> April 2026